Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.

Andersson, Gustav; Wennersten, Christoffer; Gaber, Alexander; Boman, Karolina; Nodin, Björn; Uhlén, Mathias; Segersten, Ulrika; Malmström, Per-Uno; Jirström, Karin

Andersson, Gustav; Wennersten, Christoffer; Gaber, Alexander; Boman, Karolina; Nodin, Björn; Uhlén, Mathias; Segersten, Ulrika; Malmström, Per-Uno; Jirström, Karin.

Affiliation

Jirström K; Department of Clinical Sciences, Oncology and Pathology, Lund University, Skåne University Hospital, Lund 221 85, Sweden. karin.jirstrom@med.lu.se.

BMC Urol ; 14: 36, 2014 May 12.

Article in En | MEDLINE | ID: mdl-24885195

Subject(s)

Biomarkers, Tumor/metabolism; Cytoskeletal Proteins/metabolism; Survival Rate; Urinary Bladder Neoplasms/diagnosis; Urinary Bladder Neoplasms/mortality; Cohort Studies; Disease-Free Survival; Down-Regulation; Female; Humans; Male; Prognosis; Proportional Hazards Models; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Sweden; Urinary Bladder Neoplasms/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Biomarkers, Tumor / Survival Rate / Cytoskeletal Proteins Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: BMC Urol Journal subject: UROLOGIA Year: 2014 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google